Evidence map›Paper›PMID 26423957›Full record

ArticleJournal of virology2015

Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.

Charles E Mays, Jacques van der Merwe, Chae Kim, Tracy Haldiman, Debbie McKenzie, Jiri G Safar, David Westaway

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Mechanisms of prion-induced toxicity.Cell and tissue research · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Quaternary Structure Changes for PrPMolecular neurobiology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Goats naturally devoid of PrPVeterinary research · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Cellular and Molecular Mechanisms of Prion Disease.Annual review of pathology · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Charles E MaysCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.
Jacques van der MerweCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.
Chae KimNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, Ohio, USA.
Tracy HaldimanNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, Ohio, USA Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Debbie McKenzieCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada Department of Biological Sciences, Division of Neurology, University of Alberta, Edmonton, Alberta, Canada.
Jiri G SafarNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, Ohio, USA Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA Department of Neurology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
David WestawayCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada Department of Biological Sciences, Division of Neurology, University of Alberta, Edmonton, Alberta, Canada Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada david.westaway@ualberta.ca.
University of Alberta · CACase Western Reserve University · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Replication mechanism of human prionsR01NS074317 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI SAFAR, JIRI G., SUREWICZ, WITOLD K · 2011 to 2015
$2.6M
Canadian Institutes of Health Research MOP36377NCATS NIH HHS UL1 TR000439NINDS NIH HHS NS074317NINDS NIH HHS R01 NS074317PHS HHS UR8/CCU515004
6 · The paper itself

Abstract

unlabelledIn lethal prion neurodegenerative diseases, misfolded prion proteins (PrP(Sc)) replicate by redirecting the folding of the cellular prion glycoprotein (PrP(C)). Infections of different durations can have a subclinical phase with constant levels of infectious particles, but the mechanisms underlying this plateau and a subsequent exit to overt clinical disease are unknown. Using tandem biophysical techniques, we show that attenuated accumulation of infectious particles in presymptomatic disease is preceded by a progressive fall in PrP(C) level, which constricts replication rate and thereby causes the plateau effect. Furthermore, disease symptoms occurred at the threshold associated with increasing levels of small, relatively less protease-resistant oligomeric prion particles (oPrP(Sc)). Although a hypothetical lethal isoform of PrP cannot be excluded, our data argue that diminishing residual PrP(C) levels and continuously increasing levels of oPrP(Sc) are crucial determinants in the transition from presymptomatic to symptomatic prion disease. IMPORTANCE: Prions are infectious agents that cause lethal brain diseases; they arise from misfolding of a cell surface protein, PrP(C) to a form called PrP(Sc). Prion infections can have long latencies even though there is no protective immune response. Accumulation of infectious prion particles has been suggested to always reach the same plateau in the brain during latent periods, with clinical disease only occurring when hypothetical toxic forms (called PrP(L) or TPrP) begin to accumulate. We show here that infectivity plateaus arise because PrP(C) precursor levels become downregulated and that the duration of latent periods can be accounted for by the level of residual PrP(C), which transduces a toxic effect, along with the amount of oligomeric forms of PrP(Sc).

Indexed as

Protein FoldingProtein MultimerizationAnimalsBrainMiceMice, TransgenicPrion DiseasesPrPSc ProteinsPrPSc Proteins

Identifiers

PMID26423957
PMCPMC4665242
OpenAlexW2217289029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.